PE Firm Thoma Bravo Makes Strategic Investment in Bluesight & Medacist Acquisition

What You Should Know: 

– Today Thoma Bravo, a private equity software investment firm, announced a strategic growth investment in Bluesight, the Medication Intelligence™ Company. Current investor New Leaf Ventures will remain invested in the business. Financial terms of the transaction were not disclosed.

– This investment will support Bluesight’s acquisition of Medacist, the lead innovator in drug diversion monitoring, and drive the growth of Bluesight’s inventory management and spend optimization offerings.

Combination Creates Leading Hospital Pharmacy Software Platform 

The combination of Bluesight and Medacist represents a significant step in tackling drug diversion, a challenge impacting patient safety and facility integrity in every healthcare organization. This partnership will seamlessly integrate Bluesight’s advanced auditing capabilities and comprehensive visibility with Medacist’s streamlined reporting and visibility tools. Healthcare organizations will have a single source of software solutions, delivering unprecedented insights into medication usage and diversion, enabling accurate predictions, targeted interventions, and improved patient outcomes.

Bluesight’s acquisition of Medacist combines two innovators in drug diversion analytics and medication management solutions that together will serve more than 2,000 hospitals across North America. Bluesight’s advanced auditing capabilities and visibility across all hospital care areas complements Medacist’s streamlined reporting and visibility tools across the health system. Healthcare organizations will have a single source of software solutions that provides insights into medication usage and diversion to allow for the most accurate predictions, targeted interventions and, ultimately, improved patient outcomes. Kevin MacDonald, Co-Founder and CEO of Bluesight, will lead the combined organization.

software
healthcare
hospital
private equity